SG11201601037YA - Antibodies and assays for detection of folate receptor 1 - Google Patents

Antibodies and assays for detection of folate receptor 1

Info

Publication number
SG11201601037YA
SG11201601037YA SG11201601037YA SG11201601037YA SG11201601037YA SG 11201601037Y A SG11201601037Y A SG 11201601037YA SG 11201601037Y A SG11201601037Y A SG 11201601037YA SG 11201601037Y A SG11201601037Y A SG 11201601037YA SG 11201601037Y A SG11201601037Y A SG 11201601037YA
Authority
SG
Singapore
Prior art keywords
assays
antibodies
detection
folate receptor
folate
Prior art date
Application number
SG11201601037YA
Inventor
Olga Ab
Daniel Tavares
Julianto Setiady
Sharron Ladd
Christina N Carrigan
Lingyun Rui
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of SG11201601037YA publication Critical patent/SG11201601037YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
SG11201601037YA 2013-08-30 2014-08-29 Antibodies and assays for detection of folate receptor 1 SG11201601037YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361872407P 2013-08-30 2013-08-30
US201361875475P 2013-09-09 2013-09-09
US201461940184P 2014-02-14 2014-02-14
PCT/US2014/053512 WO2015031815A2 (en) 2013-08-30 2014-08-29 Antibodies and assays for detection of folate receptor 1

Publications (1)

Publication Number Publication Date
SG11201601037YA true SG11201601037YA (en) 2016-03-30

Family

ID=52587498

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201907501Q SG10201907501QA (en) 2013-08-30 2014-08-29 Antibodies and assays for detection of folate receptor 1
SG10202100275TA SG10202100275TA (en) 2013-08-30 2014-08-29 Antibodies and assays for detection of folate receptor 1
SG11201601037YA SG11201601037YA (en) 2013-08-30 2014-08-29 Antibodies and assays for detection of folate receptor 1

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201907501Q SG10201907501QA (en) 2013-08-30 2014-08-29 Antibodies and assays for detection of folate receptor 1
SG10202100275TA SG10202100275TA (en) 2013-08-30 2014-08-29 Antibodies and assays for detection of folate receptor 1

Country Status (28)

Country Link
US (5) US9637547B2 (en)
EP (2) EP3038650B1 (en)
JP (4) JP2016536330A (en)
KR (3) KR102585409B1 (en)
CN (2) CN105814079B (en)
AU (3) AU2014312086B2 (en)
BR (1) BR112016003665B1 (en)
CA (2) CA3222465A1 (en)
CY (1) CY1124428T1 (en)
DK (1) DK3038650T3 (en)
ES (1) ES2883191T3 (en)
HK (1) HK1222402A1 (en)
HR (1) HRP20211317T1 (en)
HU (1) HUE055856T2 (en)
IL (2) IL244061B (en)
LT (1) LT3038650T (en)
MX (2) MX371496B (en)
MY (1) MY176282A (en)
NZ (1) NZ717140A (en)
PL (1) PL3038650T3 (en)
PT (1) PT3038650T (en)
RS (1) RS62240B1 (en)
RU (1) RU2725825C2 (en)
SG (3) SG10201907501QA (en)
SI (1) SI3038650T1 (en)
UA (1) UA120166C2 (en)
WO (1) WO2015031815A2 (en)
ZA (1) ZA201907806B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230044026A (en) 2010-02-24 2023-03-31 이뮤노젠 아이엔씨 Folate receptor 1 antibodies and immunoconjugates and uses thereof
ES2661466T3 (en) * 2011-04-01 2018-04-02 Immunogen, Inc. Methods to increase the effectiveness of cancer therapy with FOLR1
HUE049693T2 (en) 2012-08-31 2020-10-28 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
HUE055856T2 (en) 2013-08-30 2021-12-28 Immunogen Inc Antibodies and assays for detection of folate receptor 1
RS59644B1 (en) * 2013-10-08 2020-01-31 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
JP2017529837A (en) 2014-09-03 2017-10-12 イミュノジェン・インコーポレーテッド Complex containing cell binding agent and cytotoxic agent
CA2981543A1 (en) * 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
JP6880006B2 (en) 2015-09-17 2021-06-02 イミュノジェン， インコーポレイテッド A therapeutic combination that includes an anti-FOLR1 immune complex
AU2018328187A1 (en) * 2017-09-05 2020-03-26 Immunogen, Inc. Methods for detection of folate receptor 1 in a patient sample
CN108152189B (en) * 2017-12-06 2020-06-05 浙江大学 Quantitative detection method for sperm surface clouding protein 1
CA3091683A1 (en) * 2018-03-13 2019-09-19 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
EA038215B1 (en) * 2018-06-09 2021-07-26 Федеральное государственное бюджетное научное учреждение "Федеральный научный центр исследований и разработки иммунобиологических препаратов им. М.П. Чумакова РАН" Method for quantitative determination of yellow fever virus antigen by enzyme immunoassay using specific yolk antibodies and biotin-labelled detector antibodies
EP3962935A4 (en) 2019-04-29 2023-05-31 Immunogen, Inc. Biparatopic fr-alpha antibodies and immunoconjugates
CA3195153A1 (en) 2020-10-27 2022-05-05 Elucida Oncology, Inc. Folate receptor targeted nanoparticle drug conjugates and uses thereof
CN112794911B (en) * 2021-04-14 2021-08-03 上海偌妥生物科技有限公司 Humanized anti-folate receptor 1 antibody and application thereof
WO2023116911A1 (en) * 2021-12-24 2023-06-29 百奥泰生物制药股份有限公司 ANTI-FRα ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
WO2023170216A1 (en) * 2022-03-11 2023-09-14 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
CN117700556B (en) * 2024-02-05 2024-04-12 苏州百道医疗科技有限公司 anti-FR alpha mouse monoclonal antibody and application thereof

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1319315A (en) 1969-06-19 1973-06-06 Citizen Watch Co Ltd Calendar timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (en) 1986-01-15 1987-07-16 Ant Nachrichtentech METHOD FOR DECODING BINARY SIGNALS AND VITERBI DECODERS AND APPLICATIONS
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US20030229208A1 (en) 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
JPH049249A (en) 1990-04-27 1992-01-14 Kusuda:Kk Facing agent spraying machine
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE463573T1 (en) 1991-12-02 2010-04-15 Medimmune Ltd PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
DK0627940T3 (en) 1992-03-05 2003-09-01 Univ Texas Use of immunoconjugates for diagnosis and / or therapy of vascularized tumors
US20030148406A1 (en) 1992-03-17 2003-08-07 David John King Multivalent antigen-binding proteins
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5432930A (en) 1993-09-30 1995-07-11 Eagle Crest Limited System for accessing cobol data files by generating a dictionary of NF.sup.2
NL9302194A (en) 1993-12-15 1995-07-03 Nidera Handelscompagnie B V Process for preparing a combined fish product, as well as fish product obtained using this process.
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE19526926A1 (en) 1995-07-24 1997-01-30 Bayer Ag Process for the production of loaded non-porous carrier materials
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
DE60044997D1 (en) 1999-07-02 2010-11-04 Morphosys Ag GENERATION OF SPECIFIC BINDING PARTNERS THAT CONNECT TO (POLY) PEPTIDES ENCODED BY GENOMIC DNA FRAGMENTS OR ESTS
IT1307309B1 (en) 1999-12-30 2001-10-30 Enea Ente Nuove Tec STABILIZING PEPTIDES, POLYPEPTIDES AND ANTIBODIES THAT INCLUDE THEM.
JP5059271B2 (en) 2000-03-31 2012-10-24 パーデュー・リサーチ・ファウンデイション Treatment methods using ligand immunogen complexes
DE10037759A1 (en) 2000-08-03 2002-07-04 Gruenenthal Gmbh screening process
EP1366455B1 (en) 2001-02-19 2008-07-02 MERCK PATENT GmbH Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
WO2002071928A2 (en) 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
CA2445826C (en) 2001-05-02 2014-03-25 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
WO2003074704A1 (en) 2002-03-01 2003-09-12 Japan Envirochemicals, Ltd. Proteins capable of binding to female sex hormones and process for producing the same
BRPI0308585B8 (en) * 2002-03-13 2021-05-25 Biogen Idec Inc isolated antibody or antigen-binding fragment thereof that binds to alfavbeta6, composition, in vitro detection method of alfavbeta6, and DNA construction
AU2003224073C1 (en) 2002-04-22 2010-03-11 AgroProtect GmbH Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
EP2213685B1 (en) * 2002-09-06 2013-11-27 Amgen Inc. Therapeutic anti-IL-1R1 monoclonal antibody
AU2003295411A1 (en) 2002-11-07 2004-06-03 Celltech R & D Human monoclonal antibodies to heparanase
EP1481993A1 (en) 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
US20080131366A1 (en) 2003-03-17 2008-06-05 Manohar Ratnam Folate Receptor Gene Modulation For Cancer Diagnosis And Therapy
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
EP1626993B1 (en) 2003-05-09 2015-03-11 Duke University Cd20-specific antibodies and methods of employing same
WO2004110498A2 (en) 2003-05-14 2004-12-23 Immunogen, Inc. Drug conjugate composition
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
KR20060030066A (en) 2003-07-02 2006-04-07 제넨테크, 인크. Compositions and methods for the diagnosis and treatment of tumor
US7622112B2 (en) 2003-12-05 2009-11-24 Jody Berry Anti-SARS monoclonal antibodies
EP3101034A1 (en) 2004-02-12 2016-12-07 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
MXPA06012162A (en) 2004-04-27 2007-03-30 Galapagos Nv Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts.
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
CA2584859C (en) 2004-10-25 2017-11-07 Merck & Co., Inc. Anti-addl antibodies and uses thereof
US20070294782A1 (en) 2004-12-21 2007-12-20 Mark Abad Transgenic plants with enhanced agronomic traits
AU2005321974B2 (en) 2004-12-27 2011-11-17 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
KR20070107687A (en) 2004-12-31 2007-11-07 제넨테크, 인크. Polypeptides that bind br3 and uses thereof
EP2153848A3 (en) 2005-01-27 2010-07-21 The Regents of the University of California Therapeutic monoclonal antibodies that neutralize botulinium neurotoxins
PT2343320T (en) 2005-03-25 2018-01-23 Gitr Inc Anti-gitr antibodies and uses thereof
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
CA2602585A1 (en) 2005-03-30 2006-10-05 Purdue Research Foundation Method for cancer prognosis using cellular folate vitamin receptor quantification
WO2006116592A2 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
US7786266B2 (en) 2005-05-12 2010-08-31 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-DSC2 antibody
EP1915394B1 (en) 2005-05-20 2021-01-27 Lonza Biologics plc. High-level expression of recombinant antibody in a mammalian host cell
US20090285795A1 (en) 2005-05-24 2009-11-19 Villoo Morawala Patell Method for the Production of a Monoclonal Antibody to CD20 for the Treatment of B-Cell Lymphoma
US20070009434A1 (en) 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
WO2007022416A2 (en) 2005-08-18 2007-02-22 Ramot At Tel Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP4938263B2 (en) * 2005-08-19 2012-05-23 独立行政法人農業生物資源研究所 Method for inhibiting cytosolic protein function using single-chain antibody and use thereof
EP3190125A1 (en) 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
US8044179B2 (en) 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
US20070099251A1 (en) 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
LT2913343T (en) 2005-12-20 2018-11-26 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
JP2009530423A (en) 2006-03-21 2009-08-27 ワイス Methods for preventing and treating amyloidogenic diseases
US8486412B2 (en) 2006-06-01 2013-07-16 Mayo Foundation For Medical Education And Research Immunity to folate receptors
US8216582B2 (en) 2006-06-23 2012-07-10 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
MY188368A (en) * 2006-09-08 2021-12-06 Abbott Lab Interleukin-13 binding proteins
EP1900752A1 (en) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
CN101594883B (en) 2006-10-12 2018-04-10 中外制药株式会社 Use the diagnosis and treatment of the cancer of anti-EREG antibody
JP5632582B2 (en) 2006-12-14 2014-11-26 中外製薬株式会社 Anti-Claudin3 monoclonal antibody and cancer treatment and diagnosis using same
JP2010513539A (en) 2006-12-20 2010-04-30 エムエムアール インフォメーション システムズ，インコーポレーテッド Antibodies and their production and use
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2609934A1 (en) 2007-02-16 2013-07-03 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
SG178804A1 (en) 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
US7915368B2 (en) * 2007-05-23 2011-03-29 Bridgestone Corporation Method for making alkoxy-modified silsesquioxanes
WO2008145136A1 (en) 2007-05-30 2008-12-04 Aarhus Universitet Stat3 inactivation by inhibition of the folate receptor pathway
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
CN101139613B (en) 2007-08-01 2011-06-08 姜荣锡 Antineoplastic dibasic polypeptide and application and preparation method thereof
RU2558260C2 (en) * 2007-12-12 2015-07-27 Пинчел Срл MEDICATIONS FOR TREATING PEMPHIGUS CONTAINING ANTIBODIES TO Fas-LIGAND
EP2227549B1 (en) 2007-12-21 2015-06-17 Novartis AG Selection system for eukaryotic cell culture based on a membrane-bound folate receptor gene
KR20100116179A (en) 2008-01-11 2010-10-29 고쿠리츠다이가쿠호우진 도쿄다이가쿠 Anti-cldn6 antibody
WO2009092010A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography
JP5470817B2 (en) 2008-03-10 2014-04-16 日産自動車株式会社 Battery electrode, battery using the same, and manufacturing method thereof
WO2009132081A2 (en) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Monoclonal antibody-based targeting of folate receptors
JP5769616B2 (en) 2008-04-30 2015-08-26 イミュノジェン・インコーポレーテッド Crosslinkers and their use
BRPI0911442A2 (en) 2008-04-30 2019-03-12 Immunogen, Inc. potent conjugates and hydrophilic binders
US8383351B2 (en) 2008-06-11 2013-02-26 Oxford Brookes University Antibody to inhibin/ activin β-B subunit
JP5675619B2 (en) 2008-09-17 2015-02-25 エンドサイト, インク.Endocyte, Inc. Folate antagonist binding conjugate of folate antagonist
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
CN101440130B (en) 2008-11-21 2011-07-27 中国人民解放军第四军医大学 Variable regions of heavy chain and light chain of antihuman IL-13R alpha 2 monoclonal antibody
MX346455B (en) 2008-12-19 2017-03-21 Medicis Pharmaceutical Corp Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis.
CN110470835A (en) 2009-03-24 2019-11-19 生物概念股份有限公司 The device and method of cell capture and analysis
EP2462161B1 (en) 2009-08-06 2017-03-08 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
JP2013507115A (en) 2009-10-09 2013-03-04 サノフイ Polypeptides for binding to "terminal glycation end product receptors" and compositions and methods comprising them
TW201129383A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
KR20230044026A (en) 2010-02-24 2023-03-31 이뮤노젠 아이엔씨 Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ602040A (en) 2010-03-24 2014-12-24 Genentech Inc Anti-lrp6 antibodies
JP2014505012A (en) 2010-10-20 2014-02-27 モーフォテック， インコーポレイテッド Antifolate receptor alpha antibody glycoforms
MX368394B (en) 2010-11-05 2019-10-01 Eisai Inc Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers.
KR20220009505A (en) 2011-03-29 2022-01-24 이뮤노젠 아이엔씨 Preparation of maytansinoid antibody conjugates by a one-step process
CN103619357A (en) 2011-03-29 2014-03-05 伊缪诺金公司 Process for manufacturing conjugates of improved homogeneity
ES2661466T3 (en) 2011-04-01 2018-04-02 Immunogen, Inc. Methods to increase the effectiveness of cancer therapy with FOLR1
US20120282282A1 (en) 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates
WO2012145112A2 (en) 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2731972B1 (en) 2011-07-15 2017-12-20 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
HUE049693T2 (en) 2012-08-31 2020-10-28 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
WO2014055842A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Process for preparing stable antibody maytansinoid conjugates
JP6136279B2 (en) 2013-01-15 2017-05-31 株式会社ジェイテクト Rolling bearing device
TWI503850B (en) 2013-03-22 2015-10-11 Polytronics Technology Corp Over-current protection device
CN105308072A (en) 2013-05-14 2016-02-03 伊缪诺金公司 Anti-folr1 immunoconjugate dosing regimens
WO2015026909A2 (en) 2013-08-23 2015-02-26 Nuclea Biotechnologies, Inc. Msia-srm assay for biomarker analysis
HUE055856T2 (en) 2013-08-30 2021-12-28 Immunogen Inc Antibodies and assays for detection of folate receptor 1
TWI510996B (en) 2013-10-03 2015-12-01 Acer Inc Methods for controlling a touch panel and portable computers using the same
RS59644B1 (en) 2013-10-08 2020-01-31 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
US20150297744A1 (en) 2014-03-28 2015-10-22 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
WO2016004233A2 (en) 2014-07-01 2016-01-07 Expression Pathology, Inc. Srm assays to chemotherapy targets
RU2741470C9 (en) 2014-09-02 2021-04-27 Иммьюноджен, Инк. Methods for preparing antibody-drug conjugate compositions
JP6880006B2 (en) 2015-09-17 2021-06-02 イミュノジェン， インコーポレイテッド A therapeutic combination that includes an anti-FOLR1 immune complex
EP3165928B1 (en) 2015-11-06 2019-01-09 Promise Advanced Proteomics A method for quantifying anti-tnf antibodies
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor
AU2018328187A1 (en) 2017-09-05 2020-03-26 Immunogen, Inc. Methods for detection of folate receptor 1 in a patient sample
WO2019060718A1 (en) 2017-09-22 2019-03-28 Immunogen, Inc. Separation of triple-light chain antibodies using cation exchange chromatography
AU2019206587A1 (en) 2018-01-12 2020-08-06 Immunogen, Inc. Methods for antibody drug conjugation, purification, and formulation
EP3962935A4 (en) 2019-04-29 2023-05-31 Immunogen, Inc. Biparatopic fr-alpha antibodies and immunoconjugates

Also Published As

Publication number Publication date
US20220169745A1 (en) 2022-06-02
WO2015031815A2 (en) 2015-03-05
SI3038650T1 (en) 2021-11-30
JP2021035968A (en) 2021-03-04
JP2019059756A (en) 2019-04-18
MX2016002537A (en) 2016-09-08
US11932701B2 (en) 2024-03-19
CY1124428T1 (en) 2022-07-22
AU2023201965A1 (en) 2023-06-01
EP3925980A1 (en) 2021-12-22
AU2014312086A1 (en) 2016-03-10
HUE055856T2 (en) 2021-12-28
DK3038650T3 (en) 2021-08-16
AU2020203507A1 (en) 2020-06-18
AU2014312086B2 (en) 2020-03-12
RU2725825C2 (en) 2020-07-06
KR20220110871A (en) 2022-08-09
CA3222465A1 (en) 2015-03-05
JP2016536330A (en) 2016-11-24
PT3038650T (en) 2021-08-25
HRP20211317T1 (en) 2021-11-26
US10017578B2 (en) 2018-07-10
JP6983746B2 (en) 2021-12-17
CN105814079B (en) 2021-02-09
CA2921975A1 (en) 2015-03-05
US10544230B2 (en) 2020-01-28
EP3038650B1 (en) 2021-05-26
MY176282A (en) 2020-07-27
KR20160055831A (en) 2016-05-18
US20170306041A1 (en) 2017-10-26
KR20230145514A (en) 2023-10-17
JP2023040115A (en) 2023-03-22
IL244061B (en) 2022-07-01
KR102428492B1 (en) 2022-08-03
UA120166C2 (en) 2019-10-25
NZ717140A (en) 2022-05-27
CA2921975C (en) 2024-02-13
US20190023805A1 (en) 2019-01-24
US20150093388A1 (en) 2015-04-02
BR112016003665B1 (en) 2024-01-09
EP3038650A4 (en) 2017-03-08
RU2016109642A (en) 2017-10-06
MX2020001160A (en) 2020-03-12
RS62240B1 (en) 2021-09-30
MX371496B (en) 2020-01-31
ZA201907806B (en) 2022-01-26
US20200325240A1 (en) 2020-10-15
IL244061A0 (en) 2016-04-21
SG10201907501QA (en) 2019-10-30
KR102585409B1 (en) 2023-10-05
SG10202100275TA (en) 2021-02-25
EP3038650A2 (en) 2016-07-06
WO2015031815A3 (en) 2015-05-07
PL3038650T3 (en) 2021-11-22
US9637547B2 (en) 2017-05-02
LT3038650T (en) 2021-09-10
AU2020203507B2 (en) 2023-04-27
RU2016109642A3 (en) 2018-09-25
HK1222402A1 (en) 2017-06-30
IL293871A (en) 2022-08-01
CN105814079A (en) 2016-07-27
BR112016003665A2 (en) 2017-12-05
ES2883191T3 (en) 2021-12-07
CN113150145A (en) 2021-07-23
US11198736B2 (en) 2021-12-14

Similar Documents

Publication Publication Date Title
ZA201907806B (en) Antibodies and assays for detection of folate receptor 1
IL280634A (en) Diagnostic assays and kits for detection of folate receptor 1
HRP20190026T1 (en) Assays for detecting the presence or amount of an anti-drug antibody
HK1216893A1 (en) Anti-tweakr antibodies and uses thereof tweakr
IL239957B (en) Evaluation and assays of pkal-mediated disorders
HRP20180664T1 (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
HK1223950A1 (en) Monoclonal olfml-3 antibodies and uses thereof olfml-3
HK1258302A1 (en) Immunoassay for the determination of fc-region modified antibodies
HK1217231A1 (en) Specific detection of rat antibodies in mouse serum